The conference will include 55 speakers at more than 44 sessions.
The first CPhI North America conference will take place in Philadelphia, PA from May 16–18, 2017. As part of the conference, CPhI will launch the Connect Conference, featuring two educational programs, CPhI Connect, focused on pharmaceuticals, and InformEx connect, focused on fine and specialty chemicals.
The Connect Conference includes 55 speakers at more than 44 sessions across eight tracks. Delegates of the Connect Conference will have access to both programs with one pass. CPhI Connect will contain four tracks, drug development, quality/regulation, drug manufacturing, and outsourcing. The program will offer perspectives on an assortment of topics in the bio/pharmaceutical industries. The following is a sampling of some of the conference speakers:
Participants in CPhI Connect will also have access to the expo floor featuring more than 450 companies across the pharma supply chain, as well as show floor programming and networking events. CPhI North America provides a complete list of the program on the conference website.
Source: CPhI North America
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
In Wake of Trump Tariffs, Lilly Plans New US Pharmaceutical Manufacturing Sites
February 26th 2025Previous domestic capital expansion commitments since 2020 had been made in Research Triangle Park and Concord, both in North Carolina; Kenosha County, Wisconsin; Lebanon, Indiana; and Lilly’s home city of Indianapolis.
Cosette Pharmaceuticals Adds to Dermatology and Women’s Health Portfolio with Mayne Pharma Purchase
Published: February 26th 2025 | Updated: February 26th 2025While the boards of directors of both companies have approved the transaction, it is not expected to close until the second quarter of 2025, as Mayne Pharma’s shareholders must still vote in favor of the acquisition.